FOLH1 and prostate carcinoma: Prostate-specific membrane antigen (PSMA) PET is a highly sensitive imaging modality used across multiple stages of prostate cancer, including initial staging, detection of biochemical recurrence, and therapy planning [44, 45] (Fig. 2).